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Summary CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated
breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological
parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N
and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive
lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had
been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well
as with the number of positive lymph nodes in pTI tumours. CA15.3 was significantly higher in medullary
than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We
conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour
burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pTI
tumours).
Thobias et al. set up in 1982 an immunoradiometric assay for
the determination of a tumour associated antigen (CA15.3)
(Tobias et al., 1985) defined through two breast specific
monoclonal antibodies (DF3, 115D8) (Hilkens et al., 1984;
Kufe et al., 1984). Several investigators were prompted to
evaluate the clinical usefulness of the new tumour marker
CA15.3 in patients with breast cancer because no breast
specific tumour marker was available as yet. Results from
clinical studies published to date show that CA15.3 is
effective in the follow-up of patients treated for primary
breast cancer. Indeed, any significant increase of the marker
may allow an early detection of relapse (Maigre et al., 1988)
and is probably related to a poorer prognosis (Krebs et al.,
1988; Pons-Anicet et al., 1988; Ruibal et al., 1987).
Moreover, the variations of CA15.3 levels are in relation to
the effectiveness of the therapy of disseminated breast cancer
(Maigre et al., 1988). Several investigations reported that
CA15.3 is more effective in the monitoring of patients with
breast cancer than the traditional 'broad spectrum' tumour
markers, with CAl 5.3 being certainly more specific and prob-
ably more sensitive than CEA (Colomer et al., 1989; Delarue
et al., 1988; Hoffman et al., 1987; Jager et al., 1986; Ruibal et
al., 1987; Schmidt et al., 1987).
In spite of the bulk of data regarding advanced breast
cancer, the relationships between CA15.3 preoperatory levels
and other clinical and biological parameters in patients with
primary breast cancer have not been thoroughly evaluated
and results are still conflicting. Indeed, it has been demon-
strated that CA15.3 has no diagnostic role in discriminating
between primary breast cancer and benign breast diseases,
due to the low positivity rate of the marker in patients with
early breast carcinoma (Gion et al., 1986b). Reported
positivity rates are widely scattered, and the relationship
between CA15.3 and tumour size, axillary metastasis and
steroid receptors has been demonstrated by some investi-
gators and denied by others. Finally, the prognostic role of
preoperatory CA15.3 levels is still to be defined.
In the present investigation we measured preoperatory
CA15.3 serum levels in 667 patients with primary breast
cancer, with the aim of identifying any relationship between
the marker and other clinical and biological parameters of
the disease in a number of cases adequate for statistical
evaluation.
Patients and methods
From 1985 to 1988 667 patients with untreated primary
breast cancer entered the study (median age 60 years, range
25-88). Cases were selected on the basis of the following
inclusion criteria: (1) no evidence of distant metastasis; (2) no
previous or concomitant malignancies in different organs; (3)
no clinical or laboratory evidence of benign disease of liver,
pancreas and ovary; (4) no radiotherapy or chemotherapy
before surgery. The characteristics of the evaluated patients
are summarised in Table I.
Serum samples from 193 apparently healthy volunteer
women (median age 50 years, range 34-78) were collected as
the control group.
Serum samples were collected before the mastectomy prior
to any drug administration, and kept frozen until the assay,
which was carried out within no more than 15 days from
sampling. Patient staging was carried out according to UICC
criteria (UICC, 1979); histologic typing was done following
the WHO classification (WHO, 1982). Oestrogen (ER) and
progesterone (PgR) receptors were measured in tumour tissue
using a radioligand binding assay (dextran-coated charcoal)
set up according to the European Organisation Research and
Treatment of Cancer standardisation criteria (EORTC,
1980). The conventional value of 10fmolmg-' of cytosol
protein was used as positive/negative cut-off for both ER and
PgR. Serum CA15.3 levels were measured by a commercially
available immunoradiometric kit (ELSA-CA15.3, CIS Diag-
nostici, Santhia, Vercelli, Italy). The method precision, ex-
pressed as coefficient of variation between 20 replicates of
human serum pools with three different antigen concentra-
tions, was lower than 8.4% intra-assay and lower than 9.6%
between assay.
Data were analysed with the Mann-Whitney test, the Wil-
coxon test, the Fisher exact test and the regression analysis
using both data and the logarithms of data. The distribution
pattern of CA15.3 in different patients subgroups was
evaluated with the Kolmogorov-Smirnov test. Survival
analysis was performed by the univariate analysis, the Cox
proportional hazard regression model (Cox, 1972) and the
product-limit method (Mantel, 1966). All tests of statistical
significance were two-tailed.
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Results
Healthy subjects
CA15.3 levels in the control group showed a distribution not
significantly different from the gaussian (Kolmogorov-
Smirnov test, P >0.1) both in the overall group of cases and
in the subgroups selected on the basis of menopausal status.
Considering the distribution pattern of the control group, the
cut-off levels were calculated using parametric criteria. The
parameters of CA15.3 concentrations in healthy subjects, as
well as several possible cut-off levels, are summarised in
Table II. CAl 5.3 levels were not significantly correlated with
age and did not show significant variations which could be
related to menopausal status. However, the antigen levels
were more scattered in older patients, showing a higher
number of cases with relatively higher levels. Therefore,
positive/negative cut-off levels in postmenopausal women
should be higher than in premenopausal ones. For practical
purposes we currently use as a cut-off point the mean + 3
standard deviations of the overall control group (31 u ml-';
in the following evaluation we also considered the mean + 2
standard deviations of the overall control group (25 u ml-').
Primary breast cancer
The positivity rates found in the overall patient series as well
as in subgroups of patients divided according to stage, pT
and number of positive lymph nodes are reported in Table
III.
Age and menopausal status A weakly significant direct cor-
relation was found between CA15.3 and age (cases 655,
correlation coefficient 0.097, P = 0.013), which was
confirmed using the logarithms of data. Even if the distribu-
tion of clinical stage, T, pT, N and the number of positive
lymph nodes was not significantly different between pre- and
postmenopausal patients, a trend towards locally more
advanced cases was found in postmenopausal than in
premenopausal patients. When stratifying patients according
to stage, tumour size, and lymph nodal involvement, no
differences of CA15.3 levels related to menopausal status
were found (data not shown).
Clinical stage The median value, the interquartile and the
10-90% percentile range of CA15.3 in stages I, II and III
are shown in Figure 1. The differences between stage I and II
were not significant (P = 0.367). The antigen concentration
was significantly higher in stage III than in stage I
(P = 0.045) and II (P = 0.006). Positivity rates were also
significantly higher in stage III than in stage I and II using
both the cut-off points (Table III).
Tumour size CA15.3 serum levels were not statistically
related to clinical T. However, the assessment of clinical T is
inaccurate and imprecise, so that pT is now considered the
only reliable parameter of tumour size. A statistically
significant direct correlation was found between CAl 5.3 and
the tumour diameter (cases 494, r = 0.106, P = 0.018).
Significantly higher levels were found in pT3 than in pTI
(P = 0.005) and pT2 (P = 0.016) (Figure 2). Positivity rates
Table I Characteristics of the evaluated patients
Menopausal status Clinical stage Histological type
Premenopausal 153 (24.7%) I 81 (12.5%) Ductal 589 (88.3%)
Perimenopausal 28 (4.5%) II 467 (71.8%) Lobular 44 (6.6%)
Postmenopausal 440 (70.8%) III 102 (15.7%) Medullary 11 (1.6%)
Other types 23 (3.5%)
pT no. ofpos. lymph. Receptor statusa
pTl 237 (48.0%) 0 311 (55.9%) ER + PgR + 401 (60.1%)
pT2 241 (48.9%) 1-3 130 (23.4%) ER + PgR-101 (15.2%)
pT3 16 (3.1%) >3 115 (20.7%) ER-PgR+ 48 (7.2%)
ER-PgR- 117 (17.5%)
'ER and PgR positive/negative cut-off: 10fmolmg-' cytosol protein.
Table II CA15.3 serum levels in apparently healthy women
Mean FP Mean FP
Cases Distrib.a Meanb s.d.b + 2s.d.b ratec + 3s.d.b rated
Overall 193 Gaussian 14.0 5.6 25.2 7 (3.6%) 30.8 1 (0.5%)
Premenopausal 77 Gaussian 13.2 4.4 22.0 1 (1.3%) 26.4 0 (0.0)
Perimenopausale 47 Gaussian 14.3 5.9 26.1 0 (0.0) 32.0 0 (0.0)
Postmenopausal 69 Gaussian 14.7 6.4 27.5 1 (1.5%) 33.9 1 (1.5%)
Differences between pre-, peri- and postmenopausal are not statistically significant. aDifferences
from the gaussian distribution were assessed by the Kolmogorov-Smimov test (P>0.1). buml'. FP
rate: false positive rate. cCases above the mean + 2 s.d. of each group (overall, pre-, peri-,
postmenopausal). dCases above the mean + 3 s.d. ofeach group (overall, pre-, peri-, postmenopausal).
eWithin 2 years from their last menstrual period.
Table III CA15.3 positivity rates
No. of cases % of cases >25u ml' % of cases >31 uml-'
Overall 667 26.1 14.8
Stage 1 81 19.3 < 9.7v
2 467 25.3 * **- - 12.4 **
3 102 ---)48.7 38.5
pT 1 237 21.5t 12.7
2 241 28.6 * 16.2
3 16 50.0k 31.2
No. of 0 311 21.9f 10.3
+lymph 1-3 130 * 22.3 *** ** + 1.5 ***
>3 115 -34I.7*3 -31.
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Figure 1 Relationship between CA15.3 serum levels and clinical
stage. Horizontal bar, median value; thin vertical bar, 10-90th
percentile range; thick vertical bar, interquartile range.
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Figure 2 Relationship between CA15.3 and pT. Horizontal bar,
median value; thin vertical bar, 10-90th percentile range; thick
vertical bar, interquartile range.
tended to be higher in pT3 than in pTl and pT2, but
differences were significant only between pT3 and pTl with
the lower cut-off point (Table III). Differences related to
tumour size were evaluated in both N - and N + cases. In
N - cases CAl 5.3 levels were significantly higher (P = 0.024)
in pT2 (median 21 u ml-', interquartile range 12.8-
26.9 u ml-', cases >31 u ml1' 16.2%) than in pTl (median
17.8 u ml-' interquartile range 13.3-21.9 u ml', cases
>31 u ml-' 5.6%). Therefore, tumour size is directly related
to CAl 5.3 serum levels in patients without axillary metas-
tasis.
Axillary lymph node status A highly significant direct cor-
relation was found between CA15.3 and the number of
positive lymph nodes (cases 556, r = 0.229, P <0.0001).
CA15.3 was significantly higher in N2 (median 28.1 uml-',
interquartile range 21.1-39.5uml-', cases >31 uml-'
41.5%) than in both NO (median 18.1 uml', interquartile
range 11.5-23.9uml1', cases >31 uml-' 10.4%; P =
0.0001) and NI (median 20.0 uml1, interquartile range
13.0- 26.7uml'1, cases >31 umlP' 15.3%; P =0.001).
However, as in the case of clinical T, the number of positive
lymph nodes is a more reliable parameter of lymph node
status than clinical N. The relationship between CA15.3 and
the number of positive lymph nodes, categorised as no
positive lymph nodes, 1-3 positive lymph nodes and more
than three positive lymph nodes are summarised in Figure 3.
CA15.3 levels were significantly higher in cases with more
than three positive lymph nodes than in both cases with 1-3
positive (P = 0.0002) and no positive lymph nodes (P <
0.0001). Positivity rates were also significantly higher in cases
with more than three positive fymph nodes than in both cases
with no positive and one to three positive lymph nodes
(Table III). However, the assessment of axillary status is
considered reliable when at least ten lymph nodes were
examined. Therefore, the relationship between CA15.3 and
the number of positive lymph nodes was re-evaluated in
patients in which pathological data of at least ten axillary
lymph nodes were reported (406 cases). Also in this group of
selected patients CA15.3 levels were significantly higher in
cases with more than three positive lymph nodes (median
22.8 uml', interquartile range 16.1-33.0 umlP, cases
>31uml1' 31.4%) than in both cases with one to three
(median 18 uml-', interquartile range 12.2-24.0 uml-,
cases >31umlP' 12.0%; P=0.0006) and those with no
positive lymph nodes (median 18.3 uml-', interquartile range
13.0-23.5uml1', cases >31 uml-' 19/204 9.3%; P =
0.0001). The relationship between CA15.3 and the number of
positive lymph nodes was further evaluated in subgroups of
patients divided according to the tumour diameter. In pTl
tumours CA15.3 levels were higher in cases with more than
three positive lymph nodes (median 25.0 uml-', interquartile
range 16.9-37.1 uml-', cases >31 uml' 44.4%) than in
both cases with one to three (median 20.3 u ml-', interquar-
tile range 12.7-26.4umlh', cases >31 umlh' 14.3%;
P = 0.028) and those with no positive lymph nodes (median
17.8 uml1, interquartile range 13.3-21.9 uml1, cases
>31 uml1' 5.9%). Moreover, CA15.3 was significantly
higher also in cases with one to three than in those with no
positive lymph nodes (P = 0.028). Axillary nodal status is
therefore related to CA15.3 serum levels independently of
tumour size when tumour burden is limited.
Histological type No statistically significant differences were
found between ductal and lobular carcinomas. CA15.3 levels
were significantly higher in medullary (median, 24.6; inter-
quartile range, 18.7-38.1 uml-') than in ductal carcinoma
(median, 19.4; interquartile range, 13.3-25.3 uml-'; P = 0.032).
Receptors status CA15.3 levels were significantly higher in
ER+PgR- than in ER-PgR+ cases (P = 0.028). The
difference disappeared after stratification of patients accord-
ing to menopausal status, due to the fact that ER+PgR-
cases are more frequent in postmenopausal patients, in which
we found a trend towards higher CA15.3 levels, while the
ER-PgR+ pattern is more common in younger patients.
Prognostic value of CA15.3 pre-operatory levels Records of
patients follow-up were available in 112 cases. The median
follow-up time was 51 months (range 24-78). In order to
investigate the CA15.3 prognostic role, several cut-off values
were evaluated. Figure 4 shows the plot of the significativity
of differences of both relapse free survival and the overall
survival between CA15.3 positive and negative cases vs the
different cut-off points. The value of 30 uml-' was the best
cut-off for both overall survival and relapse free survival.
Using this value the prognostic role of CA15.3 was corrected
for the other known prognostic parameters (multivariate
analysis). Results, reported in Table IV, show that CA15.3
has no autonomous prognostic value.
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Figure 4 Maximal likelihood determination of the cut-off value
of CA15.3 for predicting disease free and overall survival in
breast cancer. P values obtained for each cut-offvalue are plotted
against the value itself.
Table IV Results of Cox multivariate analysis on disease free (DFS)
and overall survival (OS)
SyrDFS SyrOS
Parameter Chi square P Chi square P
pN 6.8 0.009 11.4 0.001
cER 3.0 0.084 16.6 0.000
cPgR 1.9 0.174 1.9 0.171
Cath-D 7.7 0.005 0.5 0.489
CA15.3 0.9 0.339 0.01 0.909
Discussion
The study of tumour markers in breast cancer has been
merely focused on patients follow-up because the early detec-
tion of relapse is a critical target in oncology. However, in
breast cancer this is true only from a theoretical point of
view, since the early detection of the relapse, given the avail-
able therapeutic tools, probably does not improve either the
patient survival or the quality of the residual life (Ciatto et
al., 1985; Kindler & Sateinhoff, 1989; Urban, 1986).
The study of serum tumour marker levels in patients bear-
ing the primary tumour probably does not affect the clinical
course of the disease more efficiently than the study of
tumour markers in the follow-up. Nevertheless, it allows an
accurate basic study of the relationships between the marker
and both clinical and pathological characteristics of the
neoplasia.
In previously published papers the relationships between
preoperatory CA15.3 levels and clinical stage, tumour size,
axillary status, and receptors status were studied anec-
dotically and results are still conflicting. Preliminary results
of our group showed a significant relationship between
CA15.3 and both tumour size and the number of positive
lymph nodes in 149 cases (Gion et al., 1986b). No relation-
ships were found between CA15.3 and tumour size or lymph
nodal status by Maigre et al. in 66 cases as well as by
Schmidt-Rhode et al. in 75 cases evaluated before mastec-
tomy (Maigre et al., 1988; Schmidt-Rhode et al., 1987). Both
Pons-Anicet et al. and Safi et al. described a direct relation
between higher CA15.3 positivity rates and both tumour size
and lymph nodal status, but they did not report any statis-
tical evaluation of their data (Pons-Anicet et al., 1987; Safi et
al., 1987). Krebs et al. described a direct relation between
CA15.3 positivity rates and tumour size, but they were not
able to show any relationship with axillary status in 407
evaluable patients (Krebs et al., 1988). On the contrary, Jager
et al. showed a higher positivity rate in N + than in N -
cases, but they did not refer to any evaluation of tumour size
(Jager et al., 1986).
In the present investigation we studied the relationships
between CAl5.3 preoperatory levels and several parameters
in a large patient series. CA15.3 levels were higher in patients
with locally more advanced disease (stage III, pT3, number
of positive lymph nodes >3). The capability of CA15.3
serum levels to detect small variations of tumour bulk was
improved when stratifying cases according to pT or axillary
status. The subdivision of patients according to tumour size
demonstrated that CAl5.3 levels in cases with smaller
tumours were also significantly related to minor differences in
axillary status. (nil vs one to three positive lymph nodes). On
the other hand, stratifying cases on the basis of axillary
status, we demonstrated that CA15.3 was capable of distin-
guishing as significantly different pTl from pT2 cases in
N-patients. Therefore, the relationships between CAl5.3 and
both pT and axillary status are probably independent. These
findings suggest that CAl5.3 serum levels are certainly
related to the tumour burden and probably to the tendency
of the malignancy to metastatise (number of positive lymph
nodes in small tumours). Surprisingly, no relationships were
found between CA15.3 and prognosis. However, the latter
evaluation was possible only in a limited number of cases.
The prognostic role of preoperatory serum CAl5.3 deter-
mination is therefore under investigation in a wider patient
series.
The higher CA15.3 levels found in medullary carcinomas,
although this histologic type represents a limited percentage
of all breast cancers, suggests that the marker may be
usefully used in the monitoring of the disease.
The lack of relationship between CA15.3 serum levels and
the receptor status indicates that the two parameters are
independent of each other. This is in agreement with both
previously published studies of our group (Gion et al., 1986a;
Gion et al., 1987), in which no relationships were found
between receptor status and cytosol CA15.3 levels, and
results of a clinical study performed by Krebs et al. (Krebs et
al., 1988).
From the above findings we can draw the following con-
clusions:
(1) CA15.3 is a parameter of both tumour bulk (tumour
size, lymph nodal status) and the tendency towards local
invasiveness (axillary metastasis in pTI tumours);
(2) significant tumour marker variations related to clinical
or pathological parameters occur within the normal range.
Therefore, quantitative information provided by a kinetic
evaluation of the time related variations of the marker
levels should be preferred to the dichotomic positive/
negative assessment (qualitative information) currently
obtained using conventional cut-off point.
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